| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Aug 2025 |  Quarterly Result Announcement | NA | 13 Aug 2025 | 749.65 | 743.45 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 742.15 | 697.00 |
Anthem Biosciences
666.80
-6.95
(-1.03%)
Market Cap
₹37,448.16 Cr
PE Ratio
73.33
Volume
1,36,927.00
Day High - Low
₹682.35 - ₹665.10
52W High-Low
₹873.50 - ₹620.00
Key Fundamentals
Market Cap
37,448.16 Cr
EPS
8.07
PB Ratio
13.75
Book Value
49.01
EBITDA
756.60
Dividend Yield
0.00 %
Industry
Healthcare Sector
Biotechnology ROE Growth %
-
Debt to Equity
0.08
Actual
Company News
View All News
Anthem Biosciences Reports Strong H1 FY26 Results with 26% Revenue Growth and 41.4% EBITDA MarginNov 12, 2025
Anthem Biosciences Limited delivered consolidated revenue of Rs. 1,090 Cr for the half-year ended September 30, 2025, with CRDMO business contributing Rs. 926 Cr and specialty ingredients Rs. 163 Cr. The company achieved EBITDA of Rs. 480 Cr with a margin of 41.4% and PAT of Rs. 309 Cr representing a 26.6% margin. Net cash position improved to Rs. 993 Cr. The company expanded its commercial molecules from 10 to 14 during the period, while late-phase molecules reduced from 10 to 6 as four moved to commercial status. Anthem commissioned CP6 and CP7 blocks adding 130 kiloliters capacity in Unit-II, with total CAPEX of Rs. 182 Cr. The company is progressing on Unit-IV development with planned Rs. 1,000 Cr investment over two years, targeting 400 kiloliters custom synthesis and 100 kiloliters fermentation capacity. Management expressed confidence in maintaining historical 20% CAGR growth trajectory and expects to operate at the upper end of 36%-37% EBITDA margin guidance.
Anthem Biosciences Limited reported violations of its insider trading code by two designated persons to stock exchanges. Srinivas L sold 674 equity shares during a trading window closure period that began October 1, 2025, through his pledgee agent despite instructing them not to sell during the restricted period. Bhuvaneswari sold 5,000 equity shares worth Rs. 41,75,000 without obtaining preclearance approval, as her previous approval had expired while she was on medical leave. The Audit Committee issued warning letters to both individuals and obtained acknowledgement letters confirming future compliance with the company's code of conduct. Both violations were treated seriously by the company, with warnings that future breaches will attract stricter disciplinary action.
Anthem Biosciences Reports Mixed Performance with Revenue Growth but Profit Decline in Q2 FY2026
Nov 08, 2025
Nov 08, 2025Anthem Biosciences Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. On a consolidated basis, the company reported total income of Rs. 5,500.27 million for Q2 FY2026 compared to Rs. 5,249.56 million in the same quarter last year. However, profit before tax declined to Rs. 2,296.03 million from Rs. 1,995.33 million year-over-year. For the half-year period, total income increased to Rs. 10,902.36 million from Rs. 8,635.50 million in the previous year, while profit before tax rose to Rs. 4,158.51 million from Rs. 3,175.09 million. The company operates through two main segments: CRDMO (Contract Research, Development and Manufacturing Organization) which generated Rs. 4,658.13 million in Q2, and Speciality Ingredients contributing Rs. 842.14 million. The Board of Directors approved these results in their meeting held on November 8, 2025. The company's equity shares are listed on NSE and BSE since July 21, 2025, following its IPO.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
666.80 | #1 37,448.16 | #4 73.33 | #1 1,930.30 | #1 30.15 | #1 451 | #2 7.10 | 49.90 | |
303.20 | 3,392.24 | 22.64 | 670.00 | 1.44 | 134 | #1 33.83 | 43.90 | |
85.00 | 110.53 | -478.06 | 4.30 | - | 0 | -102.70 | 15.11 | |
28.85 | 63.80 | #1 15.79 | 51.50 | 13.19 | 7 | -82.69 | 44.99 | |
0.60 | 23.90 | - | 24.40 | 14.55 | 0 | -100.00 | 28.03 | |
24.00 | 7.30 | 72.73 | 0.80 | #1 300.00 | 0 | -100.00 | 39.60 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
30.15 %
Net Income Growth
22.87 %
Cash Flow Change
198.49 %
ROE
-1.83 %
ROCE
13.75 %
EBITDA Margin (Avg.)
2.22 %
Corporate Action
Mutual Fund Holdings
Quant Mid Cap Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
HDFC Pharma And Healthcare Fund Direct - Growth 
Kotak Small Cap Fund Direct-Growth 
Mirae Asset Small Cap Fund Direct-Growth 
Motilal Oswal Manufacturing Fund Direct-Growth 
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth 
Mahindra Manulife Manufacturing Fund Direct - Growth 
SBI Healthcare Opportunities Fund Direct Plan-Growth 
UTI Healthcare Fund Direct-Growth 
LIC MF Dividend Yield Fund Direct - Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Groww Multicap Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 49.90
ATR(14)
Volatile 22.22
STOCH(9,6)
Neutral 73.83
STOCH RSI(14)
Overbought 90.68
MACD(12,26)
Bullish 8.15
ADX(14)
Weak Trend 23.54
UO(9)
Bearish 61.41
ROC(12)
Uptrend And Accelerating 6.15
WillR(14)
Neutral -33.64
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
